Drug intelligence / Profile preview

COVID-19 (Variant) Vaccine (VLP Therapeutics)

Development stage
Unknown
Lead developer
VLP Therapeutics Japan
Modality
Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

COVID-19 (Variant) Vaccine is a virus-like particle (VLP) vaccine candidate developed by VLP Therapeutics. It is specifically designed to provide protection against variant strains of the SARS-CoV-2 virus. The vaccine utilizes a VLP platform to present viral antigens, such as the spike protein, in a highly organized, repetitive array that mimics the native structure of the virus without being infectious. This presentation is intended to stimulate a robust and broad immune response, including the production of neutralizing antibodies and the activation of T-cells, to prevent infection and disease caused by emerging COVID-19 variants. The candidate is currently in early-stage clinical development.

Other names
SARS-CoV-2 (variant) vaccineVLP-based COVID-19 variant vaccineCOVID-19 (variant) vaccine-VLP The Vaccines Company
02

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on COVID-19 (Variant) Vaccine (VLP Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVID-19 (Variant) Vaccine (VLP Therapeutics).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call